Search

Jolan S Rozmanith

from Winchester, MA
Age ~93
Get Report
Also known as:
Anthony F Rozmanith, Anthony I Rozmanith, Rozmanith Js
Phone and address:
50 Middlesex St, Winchester, MA 01890
(781) 729-3770
Related to:
Rebecca S Jackson
Connected to:
James E Rozmarek, 73Kaley A Rozmarynoski, 39Andrew S Rozmiarek, 43Edward J Rozmiarek, 60Grzegorz K Rozmiarek, 59Mark V Rozmiarek, 65Mary K Rozmyslovicz, 69Brad W RoznerFrank A Rozner, 71James E Rozner, 46

Jolan Rozmanith Phones & Addresses

  • 50 Middlesex St, Winchester, MA 01890 (781) 729-3770
  • 52 Middlesex St, Winchester, MA 01890 (781) 721-1369
  • 494 Riverside Ave, Medford, MA 02155 (781) 396-0685
  • Goffstown, NH
  • 402 Swarthmore Ave, Ridley Park, PA 19078 (610) 522-5779
  • Cherry Hill, NJ
  • San Francisco, CA

Professional Records

License Records

Jolan S Rozmanith

Address:
Cherry Hill, NJ
License #:
22DI01132900 - Expired
Category:
Dentistry
Issued Date:
Jan 7, 1977
Expiration Date:
Oct 31, 1997
Type:
Dentist

Jolan S Rozmanith

Address:
Cherry Hill, NJ
License #:
22DI01132900 - Expired
Category:
Dentistry
Issued Date:
Jan 7, 1977
Expiration Date:
Oct 31, 1997
Type:
Dentist

Resumes

Resumes

Jolan Rozmanith Photo 1

Retired

Location:
Winchester, MA

Publications

Us Patents

Health Care

US Patent:
20110144055, Jun 16, 2011
Filed:
Sep 4, 2009
Appl. No.:
12/671072
Inventors:
Anthony I. Rozmanith - Winchester MA, US
Jolan S. Rozmanith - Winchester MA, US
International Classification:
A61K 31/60
A61K 31/702
A61P 29/00
A61P 9/00
A61P 3/10
A61P 25/28
US Classification:
514 61, 514163, 514162
Abstract:
The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.

Health Care

US Patent:
20200276213, Sep 3, 2020
Filed:
Mar 12, 2020
Appl. No.:
16/816630
Inventors:
Anthony I. Rozmanith - Winchester MA, US
Jolan S. Rozmanith - Winchester MA, US
International Classification:
A61K 31/60
A61K 31/167
A61K 31/192
A61K 31/18
A61K 31/155
A61K 9/20
A61K 9/00
A61K 45/06
A61K 31/64
Abstract:
The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.

Health Care

US Patent:
20180008618, Jan 11, 2018
Filed:
Jul 7, 2017
Appl. No.:
15/644276
Inventors:
Anthony I. Rozmanith - Winchester MA, US
Jolan S. Rozmanith - Winchester MA, US
International Classification:
A61K 31/60
A61K 31/18
A61K 31/167
A61K 31/155
A61K 9/20
A61K 31/192
A61K 9/00
Abstract:
The treatment of Type 2 diabetes involving the use of a regimen comprising: (A) one or more glucose-lowering drugs (G-LDs) which function to lower the amount of glucose in the blood, preferably glyburide and metformin; (B) at least one non-steroidal anti-inflammatory drug (NSAID) selected from the group consisting of (1) magnesium salicylate tetrahydrate (hereafter “Mg salicylate”); (2) naproxen; and (3) ibuprofen; and (C) acetaminophen. Also, a regimen for use in deterring the development in an individual of a cardiovascular disease or of Alzheimer's and/or for treating individuals who are affected with such diseases, the regimen comprising aforementioned ingredients (B) and (C) above.

Health Care

US Patent:
20140155349, Jun 5, 2014
Filed:
Jun 10, 2013
Appl. No.:
13/913891
Inventors:
Anthony I. Rozmanith - Winchester MA, US
Jolan S. Rozmanith - Winchester MA, US
International Classification:
A61K 31/60
A61K 31/702
A61K 31/155
A61K 31/192
A61K 31/18
US Classification:
514 61, 514163, 514162
Abstract:
The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.
Control profile
Jolan S Rozmanith from Winchester, MA, age ~93 Get Report